Longevity & AgingFDA Approves First Drug for MCT8 Deficiency Bypassing Broken Thyroid Transporter
The FDA has approved Emcitate (tiratricol) as the first treatment for MCT8 deficiency, a rare X-linked genetic disorder primarily affecting males. The condition prevents thyroid hormone from reaching the brain, causing intellectual disability, inability to walk or speak, and serious cardiovascular and metabolic stress. Tiratricol works by entering cells without the faulty MCT8 transporter, lowering excess thyroid hormone in the bloodstream. Two clinical studies, including a randomized controlled trial, showed reductions in thyroid hormone levels and improvements in heart rate and blood pressure. The drug is taken once daily as a liquid suspension, accessible even to patients with swallowing difficulties.
